{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116598","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.939116+00:00","generated_at":"2026-06-08T04:48:32.359842+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Milestone's etripamil Phase 2 meets primary endpoint; 30 bpm ventricular rate reduction vs placebo","bullets":["Mean ventricular rate reduction of 29.91 bpm vs placebo (p<0.0001); absolute max reduction 35 bpm etripamil vs 5 bpm placebo.","58.3% of etripamil patients achieved <100 bpm vs 4% placebo; median time to max reduction 13 min, effect ~150 min.","TSQM-9 patient-reported symptom relief significantly improved: effectiveness (p<0.0001) and relief of symptoms (p=0.0002).","Safety consistent with PSVT program; SAEs rare: one patient with transient severe bradycardia/syncope resolved.","Company plans Phase 3 trial; NDA for etripamil in PSVT already submitted with FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116598","json":"https://secwatch.observer/filing/0001104659-23-116598.json","markdown":"https://secwatch.observer/filing/0001104659-23-116598.md","text":"https://secwatch.observer/filing/0001104659-23-116598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923116598/0001104659-23-116598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923116598/tm2330492d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:48:32.359842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}